top of page
gradientForSurfBreak.png

Item List

Oct 21, 2024
Businesswire
Epitel Expands AI Portfolio With A Fourth FDA 510(k) Clearance for REMI

Epitel, a leader in AI for patient-focused brain health technologies, announced today it received U.S. Food and Drug Administration (FDA) 510(k) clearance for REMI Vigilenz™ AI For Bedside Notifications. REMI Vigilenz AI For Bedside Notifications conducts an automated analysis of EEG data collected by the REMI™ wireless wearable EEG System in near real-time. Notifications occur when the algorithm recognizes seizure characteristics within a section of EEG.

Recent Posts

Portfolio Company

Carlsmed.png

Tombot Closes $7 Million Series A3 Growth Financing to Scale Operations and Expa ...

Businesswire

Jun 25, 2026

Portfolio Company

Carlsmed.png

Gradient Health Expands Atlas Beyond Imaging to Deliver Multimodal Data for Medi ...

Gradient

Jun 16, 2026

Portfolio Company

Carlsmed.png

Digital medical device for cancer detection certified for smartphone use ...

Med-Tech Insights

Jun 16, 2026

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page